SI3204359T1 - Tetrahidroizokinolinski derivati - Google Patents

Tetrahidroizokinolinski derivati

Info

Publication number
SI3204359T1
SI3204359T1 SI201531348T SI201531348T SI3204359T1 SI 3204359 T1 SI3204359 T1 SI 3204359T1 SI 201531348 T SI201531348 T SI 201531348T SI 201531348 T SI201531348 T SI 201531348T SI 3204359 T1 SI3204359 T1 SI 3204359T1
Authority
SI
Slovenia
Prior art keywords
tetrahydroisoquinoline derivatives
tetrahydroisoquinoline
derivatives
Prior art date
Application number
SI201531348T
Other languages
English (en)
Slovenian (sl)
Inventor
Anne Valade
Eric Jnoff
Ali Ates
Pierre Burssens
David Skolc
Zara Sands
Benoit Mathieu
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of SI3204359T1 publication Critical patent/SI3204359T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Epidemiology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
SI201531348T 2014-10-08 2015-10-06 Tetrahidroizokinolinski derivati SI3204359T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14188174 2014-10-08
EP15775688.3A EP3204359B1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives
PCT/EP2015/073053 WO2016055479A1 (en) 2014-10-08 2015-10-06 Tetrahydroisoquinoline derivatives

Publications (1)

Publication Number Publication Date
SI3204359T1 true SI3204359T1 (sl) 2020-10-30

Family

ID=51790569

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531348T SI3204359T1 (sl) 2014-10-08 2015-10-06 Tetrahidroizokinolinski derivati

Country Status (18)

Country Link
US (1) US10105359B2 (enExample)
EP (1) EP3204359B1 (enExample)
JP (1) JP6622299B2 (enExample)
CN (1) CN107001278B (enExample)
BR (1) BR112017007123B1 (enExample)
CA (1) CA2963951C (enExample)
CY (1) CY1123417T1 (enExample)
DK (1) DK3204359T3 (enExample)
EA (1) EA035544B1 (enExample)
ES (1) ES2821821T3 (enExample)
HR (1) HRP20201469T1 (enExample)
HU (1) HUE050664T2 (enExample)
LT (1) LT3204359T (enExample)
PL (1) PL3204359T3 (enExample)
PT (1) PT3204359T (enExample)
RS (1) RS60933B1 (enExample)
SI (1) SI3204359T1 (enExample)
WO (1) WO2016055479A1 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108884077A (zh) * 2016-02-25 2018-11-23 阿森纽荣股份公司 糖苷酶抑制剂
CN108884050B (zh) 2016-04-13 2022-07-05 Ucb生物制药私人有限公司 四氢异喹啉衍生物
CN107698433A (zh) * 2017-09-12 2018-02-16 潍坊滨海石油化工有限公司 苯乙酸的制备方法
ES2899679T3 (es) 2017-12-01 2022-03-14 UCB Biopharma SRL Agentes de formación de imágenes
TWI725408B (zh) * 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑
MX2021015872A (es) * 2019-07-01 2022-02-03 UCB Biopharma SRL Un derivado de tetrahidroisoquinolina sustituido como modulador alosterico positivo de d1.
PH12021552825A1 (en) * 2019-07-01 2022-10-03 UCB Biopharma SRL A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
US20230255934A1 (en) * 2020-04-24 2023-08-17 The Regents Of The University Of California Nurr1 receptor modulators and uses thereof
CN111943930B (zh) * 2020-08-25 2022-11-01 南京三元阳普医药科技有限公司 Lasmiditan的合成工艺
EP4200280B1 (en) * 2020-10-07 2024-02-21 Eli Lilly And Company Phenyl-3,4-dihydroisoquinolin-2(1h)-yl-ethan-1-one derivatives as dopamine d1 receptor positive allosteric modulators
EP4267555A1 (en) 2020-12-03 2023-11-01 UCB Biopharma SRL Octahydroisoquinolinyl derivatives
ES3004257T3 (en) * 2020-12-18 2025-03-12 UCB Biopharma SRL Prodrugs of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1s,3r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1h-isoquinolin-2-yl]ethanone
CA3202106A1 (en) 2020-12-18 2022-06-23 Adrian Hall Dihydroisoquinolinyl derivatives
CN116685308A (zh) * 2020-12-18 2023-09-01 Ucb生物制药有限责任公司 无定形固体分散体
SI4263517T1 (sl) * 2020-12-18 2025-01-31 UCB Biopharma SRL Substituiran tetrahidroizokinolinski derivat kot pozitivni alosterični modulator d1
US20240299375A1 (en) 2021-03-08 2024-09-12 Eli Lilly And Company Use of mevidalen and other d1 positive allosteric modulators in the treatment of hallucinations and dementia-related psychosis
CN117337173A (zh) 2021-03-09 2024-01-02 伊莱利利公司 美维达林和其他d1正向别构调节剂用于减缓帕金森氏病进展的用途
CN114671810B (zh) * 2022-03-21 2024-03-22 济南鸿湾生物技术有限公司 一种咪唑苯脲的制备方法
CN115611768B (zh) * 2022-11-14 2024-03-05 郑州大学 一种3,4-二氯苯腈的合成方法
CN118724764B (zh) * 2024-06-07 2025-11-18 绍兴文理学院 一种芳基伯磺酰胺类化合物的制备方法
CN119569653B (zh) * 2024-11-25 2026-04-14 滁州市庆云医药有限公司 一种罗沙司他中间体的制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766131A (en) * 1980-10-17 1988-08-23 Pennwalt Corporation 2-amino (or hydroxy) phenethyl-1,2,3,4-tetrahydroisoquinolines as analgesics
AU2002351733A1 (en) * 2001-12-19 2003-06-30 H. Lundbeck A/S 3,4-dihydro-1h-isoquinoloin-2-yl-derivatives
ES2342083T3 (es) * 2004-04-29 2010-07-01 Aventis Pharmaceuticals Inc. 3-piperidinilisocroman-5-oles como agonistas de dopamina.
JP2010520217A (ja) * 2007-03-01 2010-06-10 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ヒスタミンh3受容体のモジュレーターとしてのテトラヒドロイソキノリン化合物

Also Published As

Publication number Publication date
PT3204359T (pt) 2020-09-24
US10105359B2 (en) 2018-10-23
EA035544B1 (ru) 2020-07-03
JP6622299B2 (ja) 2019-12-18
BR112017007123B1 (pt) 2023-01-31
EA201790785A1 (ru) 2017-10-31
HRP20201469T1 (hr) 2020-12-11
HUE050664T2 (hu) 2020-12-28
DK3204359T3 (da) 2020-09-14
EP3204359A1 (en) 2017-08-16
EP3204359B1 (en) 2020-07-01
CA2963951A1 (en) 2016-04-14
RS60933B1 (sr) 2020-11-30
CN107001278A (zh) 2017-08-01
LT3204359T (lt) 2020-10-12
PL3204359T3 (pl) 2021-03-22
JP2017530185A (ja) 2017-10-12
BR112017007123A2 (pt) 2017-12-19
CN107001278B (zh) 2020-11-24
ES2821821T3 (es) 2021-04-27
WO2016055479A1 (en) 2016-04-14
US20170304292A1 (en) 2017-10-26
CY1123417T1 (el) 2021-12-31
CA2963951C (en) 2023-02-28

Similar Documents

Publication Publication Date Title
PT3204359T (pt) Derivados de tetra-hidroisoquinolinas
AU361515S (en) Dishrack
AU362944S (en) Lapboard
IL253381A0 (en) History of h9-pyrrolo-dipyridine
SG11201609205WA (en) Heterocyclyl-butanamide derivatives
PL3164393T3 (pl) Pochodne flawaglin
HUE050450T2 (hu) Fluoralkil-fluorén-származékok
PL3233890T3 (pl) Pestiwirus
IL248773A0 (en) History of naphthyridinedione
IL251005B (en) Pyrido-oxazinone derivatives
IL261055B (en) Tetrahydroisoquinoline derivatives
PL3119744T3 (pl) Pochodne 2-cyjano-3-cyklopropylo-3-hydroksy-N-arylo-tioakryloamidu
AP2016009530A0 (en) Cycloalkyl-linked diheterocycle derivatives
SMT201900438T1 (it) Nuovi derivati di cyp-eicosanoide
GB201409664D0 (en) Tracers
GB2530305B (en) Tracers
GB201707862D0 (en) Tracers
GB201418365D0 (en) Tracers
AU5584P (en) Laniowa Mandevilla sanderi
AU5583P (en) Lanminnesota Mandevilla sanderi
AU5596P (en) Lannevada Mandevilla sanderi
AU5287P (en) FLOMANPIW Mandevilla sanderi
AU5286P (en) FLOMANWHW Mandevilla sanderi
AU5288P (en) FLOMANTOG Mandevilla sanderi
AU5289P (en) FLOMANFOP Mandevilla sanderi